|
JPS6041077B2
(ja)
|
1976-09-06 |
1985-09-13 |
喜徳 喜谷 |
１，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
|
|
US4261989A
(en)
|
1979-02-19 |
1981-04-14 |
Kaken Chemical Co. Ltd. |
Geldanamycin derivatives and antitumor drug
|
|
US5266573A
(en)
|
1989-08-07 |
1993-11-30 |
Elf Sanofi |
Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders
|
|
EP0647450A1
(en)
|
1993-09-09 |
1995-04-12 |
BEHRINGWERKE Aktiengesellschaft |
Improved prodrugs for enzyme mediated activation
|
|
DE69536015D1
(de)
|
1995-03-30 |
2009-12-10 |
Pfizer Prod Inc |
Chinazolinone Derivate
|
|
US5763263A
(en)
|
1995-11-27 |
1998-06-09 |
Dehlinger; Peter J. |
Method and apparatus for producing position addressable combinatorial libraries
|
|
EA001595B1
(ru)
|
1996-04-12 |
2001-06-25 |
Варнер-Ламберт Компани |
Необратимые ингибиторы тирозинкиназ
|
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
PT1154774E
(pt)
|
1999-02-10 |
2005-10-31 |
Astrazeneca Ab |
Derivados de quinazolina como inibidores de angiogenese
|
|
HK1044769B
(zh)
|
1999-06-21 |
2005-02-25 |
贝林格尔英格海姆法玛两合公司 |
雙環雜環化合物，含有該化合物的藥物組合物，該化合物的用途及其製備方法
|
|
PE20010306A1
(es)
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
|
WO2001077104A1
(de)
|
2000-04-08 |
2001-10-18 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
|
DE10042061A1
(de)
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
AU9598601A
(en)
|
2000-10-20 |
2002-04-29 |
Eisai Co Ltd |
Nitrogenous aromatic ring compounds
|
|
DE10063435A1
(de)
|
2000-12-20 |
2002-07-04 |
Boehringer Ingelheim Pharma |
Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
CA2442742A1
(en)
|
2001-02-21 |
2002-08-29 |
Mitsubishi Pharma Corporation |
Quinazoline derivatives
|
|
ES2263743T3
(es)
|
2001-04-13 |
2006-12-16 |
Pfizer Products Inc. |
Derivados de 4-aminopiridopirimidina sustituidos con un grupo biciclico.
|
|
IL160971A0
(en)
|
2001-11-30 |
2004-08-31 |
Pfizer Prod Inc |
Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
|
|
PT1478648E
(pt)
|
2002-02-01 |
2014-07-15 |
Ariad Pharma Inc |
Compostos contendo fósforo e suas utilizações
|
|
CN100430052C
(zh)
|
2002-03-05 |
2008-11-05 |
默克弗罗斯特加拿大有限公司 |
组织蛋白酶半胱氨酸蛋白酶抑制剂
|
|
DE10217689A1
(de)
*
|
2002-04-19 |
2003-11-13 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
|
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
|
PE20040945A1
(es)
|
2003-02-05 |
2004-12-14 |
Warner Lambert Co |
Preparacion de quinazolinas substituidas
|
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
|
AU2004272346A1
(en)
|
2003-09-16 |
2005-03-24 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
KR20080095915A
(ko)
|
2004-05-06 |
2008-10-29 |
워너-램버트 캄파니 엘엘씨 |
4-페닐아미노-퀴나졸린-6-일-아미드
|
|
CN101010304A
(zh)
*
|
2004-09-01 |
2007-08-01 |
三菱制药株式会社 |
分子伴侣功能调节剂
|
|
ES2377430T3
(es)
|
2004-09-02 |
2012-03-27 |
Genentech, Inc. |
Inhibidores piridílicos de la señalización de hedgehog
|
|
KR101313702B1
(ko)
|
2005-02-03 |
2013-10-04 |
와이어쓰 |
제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
PE20070207A1
(es)
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
|
WO2007055513A1
(en)
|
2005-11-08 |
2007-05-18 |
Hanmi Pharm. Co., Ltd. |
Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof
|
|
KR100832594B1
(ko)
|
2005-11-08 |
2008-05-27 |
한미약품 주식회사 |
다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
|
|
KR20080015594A
(ko)
|
2006-08-16 |
2008-02-20 |
주식회사종근당 |
포스포디에스테라제 저해제로서 유용한 퀴나졸린 유도체 및그 제조방법
|
|
AU2007296746B2
(en)
|
2006-09-11 |
2012-07-05 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
|
TWI377944B
(en)
|
2007-06-05 |
2012-12-01 |
Hanmi Holdings Co Ltd |
Novel amide derivative for inhibiting the growth of cancer cells
|
|
WO2008157500A1
(en)
|
2007-06-17 |
2008-12-24 |
Kalypsys, Inc. |
Aminoquinazoline cannabinoid receptor modulators for treatment of disease
|
|
EP2205242B1
(en)
|
2007-09-12 |
2015-04-15 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
|
JP5348725B2
(ja)
|
2007-10-25 |
2013-11-20 |
ジェネンテック， インコーポレイテッド |
チエノピリミジン化合物の製造方法
|
|
US8168784B2
(en)
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
|
US9006252B2
(en)
|
2008-09-26 |
2015-04-14 |
National Health Research Institutes |
Fused multicyclic compounds as protein kinase inhibitors
|
|
EP2448409A4
(en)
|
2009-07-02 |
2013-04-10 |
Newgen Therapeutics Inc |
PHOSPHOROUS CHINAZOLIN COMPOUNDS AND METHOD OF USE THEREOF
|
|
CN105037333A
(zh)
|
2009-12-21 |
2015-11-11 |
张强 |
新的喹唑啉衍生物
|
|
CN102382065B
(zh)
|
2010-08-30 |
2014-05-28 |
山东轩竹医药科技有限公司 |
苯胺取代的喹唑啉衍生物
|
|
CN102382106A
(zh)
|
2010-08-30 |
2012-03-21 |
黄振华 |
苯胺取代的喹唑啉衍生物
|
|
CN102452989B
(zh)
|
2010-10-19 |
2014-10-22 |
山东轩竹医药科技有限公司 |
苯胺取代的喹唑啉衍生物
|
|
WO2012122058A2
(en)
*
|
2011-03-04 |
2012-09-13 |
Newgen Therapeutics, Inc. |
Alkyne substituted quinazoline compound and methods of use
|
|
CN102731485B
(zh)
|
2011-04-02 |
2016-06-15 |
齐鲁制药有限公司 |
4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
|
|
WO2012155339A1
(zh)
|
2011-05-17 |
2012-11-22 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
|
TWI577693B
(zh)
|
2011-05-31 |
2017-04-11 |
江蘇康緣藥業股份有限公司 |
聚（ａｄｐ-核糖）聚合酶之三環抑制劑
|
|
AU2012282076A1
(en)
|
2011-07-13 |
2014-02-27 |
Novartis Ag |
4 - piperidinyl compounds for use as tankyrase inhibitors
|
|
JP6437820B2
(ja)
|
2011-07-27 |
2018-12-12 |
シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド |
キナゾリン誘導体、その製造方法、中間体、組成物及びその適用
|
|
CN102516232A
(zh)
|
2011-12-14 |
2012-06-27 |
无锡美克赛医药科技有限公司 |
一种ErbB2的小分子选择性抑制剂及其应用
|
|
WO2013131424A1
(zh)
|
2012-03-09 |
2013-09-12 |
上海恒瑞医药有限公司 |
4-喹唑啉胺类衍生物及其用途
|
|
US9550738B2
(en)
|
2012-05-14 |
2017-01-24 |
Hangzhouderenyucheng Biotechnology Ltd |
Bicyclic compounds as kinases inhibitors
|
|
RS58514B1
(sr)
|
2012-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Supstituisana triciklična jedinjenja kao inhibitori fgfr
|
|
CN102942561A
(zh)
|
2012-11-06 |
2013-02-27 |
深圳海王药业有限公司 |
4-氨基喹唑啉杂环化合物及其用途
|
|
CN103965120B
(zh)
|
2013-01-25 |
2016-08-17 |
上海医药集团股份有限公司 |
喹啉及喹唑啉衍生物、制备方法、中间体、组合物及应用
|
|
TWI609012B
(zh)
|
2013-04-28 |
2017-12-21 |
廣東東陽光藥業有限公司 |
氨基喹唑啉類衍生物及其鹽和使用方法
|
|
CN104513229A
(zh)
|
2013-09-28 |
2015-04-15 |
正大天晴药业集团股份有限公司 |
喹唑啉衍生物及其制备方法
|
|
EP3055290B1
(en)
|
2013-10-10 |
2019-10-02 |
Araxes Pharma LLC |
Inhibitors of kras g12c
|
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
|
EP3181553B1
(en)
|
2014-08-15 |
2019-12-11 |
Arromax Pharmatech Co., Ltd. |
Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof
|
|
WO2016055982A1
(en)
|
2014-10-10 |
2016-04-14 |
Acerta Pharma B.V. |
Quinoline and quinazoline compounds
|
|
US20180193274A1
(en)
|
2014-12-24 |
2018-07-12 |
Principia Biopharma Inc. |
Compositions for ileo-jejunal drug delivery
|
|
US10287266B2
(en)
*
|
2015-06-19 |
2019-05-14 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
|
US9890187B2
(en)
|
2015-06-26 |
2018-02-13 |
Epos-Iasis Research And Development, Ltd. |
Prototype systems of theranostic biomarkers for in vivo molecular management of cancer
|
|
GB201517216D0
(en)
|
2015-09-29 |
2015-11-11 |
Cancer Res Technology Ltd And Astex Therapeutics Ltd |
Pharmaceutical compounds
|
|
SG11201804901WA
(en)
|
2015-12-22 |
2018-07-30 |
SHY Therapeutics LLC |
Compounds for the treatment of cancer and inflammatory disease
|
|
CN105348271A
(zh)
|
2015-12-23 |
2016-02-24 |
常州润诺生物科技有限公司 |
喹唑啉类衍生物药用用途及其制备方法
|
|
US20220041613A1
(en)
|
2018-09-25 |
2022-02-10 |
Black Diamond Therapeutics, Inc. |
Tyrosine kinase inhibitor compositions, methods of making and methods of use
|
|
JP2022502495A
(ja)
|
2018-09-25 |
2022-01-11 |
ブラック ダイアモンド セラピューティクス，インコーポレイティド |
チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用
|
|
CN109265449B
(zh)
|
2018-11-07 |
2021-11-23 |
沈阳工业大学 |
Egfr和her2双靶点酪氨酸激酶抑制剂及制备方法和用途
|
|
WO2020139748A1
(en)
|
2018-12-28 |
2020-07-02 |
Cedars-Sinai Medical Center |
Methods of treating inflammatory bowel diseases that target ripk2
|
|
AU2020328598A1
(en)
|
2019-08-15 |
2022-03-03 |
Black Diamond Therapeutics, Inc. |
Alkynyl quinazoline compounds
|
|
WO2021154997A1
(en)
|
2020-01-29 |
2021-08-05 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of apol1 and methods of using same
|
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
|
US11608343B2
(en)
|
2020-04-24 |
2023-03-21 |
Boehringer Ingelheim International Gmbh |
Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
|
|
WO2022040377A1
(en)
|
2020-08-20 |
2022-02-24 |
Black Diamond Therapeutics, Inc. |
Methods for preparing quinazoline derivatives
|
|
WO2022076671A1
(en)
|
2020-10-08 |
2022-04-14 |
Black Diamond Therapeutics, Inc. |
Method of treating cancers using quinazoline derivatives
|
|
US20240075042A1
(en)
|
2020-11-02 |
2024-03-07 |
Black Diamond Therapeutics, Inc. |
Method of treating cancers with alkyne substituted quinazoline derivatives
|
|
CA3231697A1
(en)
|
2021-09-21 |
2023-03-30 |
Black Diamond Therapeutics, Inc. |
Polymorphs as erbb inhibitors
|
|
WO2025038731A1
(en)
|
2023-08-15 |
2025-02-20 |
Black Diamond Therapeutics, Inc. |
Method of treating cancers with alkyne substituted quinazoline derivatives
|